A Phase 1 Study of Single-dose Subcutaneous E6011 in Japanese Healthy Adult Male Subjects

NCT02146261 | Completed Phase 1

• 1 other identifier: E6011-J081-002
• Study Type: interventional
• Target: 32
• Locations: 1 country
• Sites: 1

Brief Summary

This study (Protocol No. E6011-J081-002) is a single-center, randomized, double-blind, placebo-controlled, single ascending dose (SAD) study to evaluate mainly the safety and tolerability of a single subcutaneous administration of E6011. A total of 32 subjects will be randomized into four cohorts (50, 100, 200 and 400 mg groups). Of eight subjects per cohort, six subjects will receive the single subcutaneous E6011 administration and two subjects will receive the single subcutaneous placebo administration.

Conditions

Healthy

Keywords

Volunteers; Japanese; Males

Outcome Measures

Primary Outcomes (8)

• Pharmacokinetics of E6011: Maximum Concentration (Cmax)

  Up to 10 Weeks

• Pharmacokinetics of E6011: Time to attain Cmax (tmax)

  Up to 10 Weeks

• Pharmacokinetics of E6011: Area Under the Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration AUC(0-t)

  Up to 10 Weeks

• Pharmacokinetics of E6011: Area Under the Plasma Concentration-time Profile From Time Zero Extrapolated to Infinite Time AUC(0-inf)

  Up to 10 Weeks

• Pharmacokinetics of E6011: Elimination half-life (t1/2)

  Up to 10 Weeks

• Pharmacokinetics of E6011: CL/F

  Apparent clearance of drug from plasma following extravascular administration (CL/F) was calculated as dose/AUC(0-?).

  Up to 10 Weeks

• Pharmacokinetics of E6011: Apparent Volume of Distribution of Azacitidine (Vz/F)

  Up to 10 Weeks

• Safety and Tolerability of E6011

  The safety will be assessed based on all adverse events (AEs), clinical laboratory test, vital signs, body weight, physical finding, administration site finding, electrocardiography and chest xray.

  Up to 10 Weeks

Study Arms (5)

1

EXPERIMENTAL

Subcutaneous administration of E6011 50 mg

Drug: E6011

2

EXPERIMENTAL

Subcutaneous administration of E6011 100 mg

Drug: E6011

3

EXPERIMENTAL

Subcutaneous administration of E6011 200 mg

Drug: E6011

4

EXPERIMENTAL

Subcutaneous administration of E6011 400 mg

Drug: E6011

5

PLACEBO COMPARATOR

Subcutaneous administration of placebo

Drug: Placebo

Interventions

E6011 DRUG

Subcutaneous administration of E6011 (at doses of 50, 100, 200 and 400 mg)

1; 2; 3; 4

Placebo DRUG

Subcutaneous administration of placebo

5

Eligibility Criteria

• Age: 20 Years - 44 Years
• Sex: male
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Non-smoking Japanese male subjects aged greater than or equal to 20 to less than 45 years
• BMI at screening is greater than or equal to 18.5 kg/m2 to less than 25.0 kg/m2
• Males who have not had a successful vasectomy and their female partners must agree to practice highly effective contraception throughout the study period

You may not qualify if:

• Has been treated with biologic product(s) (except for immunoglobulin)
• Has received immunoglobulin or blood preparation within 6 months before the study treatment
• Has received inoculation within 4 weeks before the study treatment
• Has a history of autoimmune disease or immunodeficiency
• Has a history of clinically significant angioedema, hematemesis, anal hemorrhage, or hemoptysis
• Has a history of acute myocardial infarction, cerebral infarction, cerebral hemorrhage, or arteriosclerosis obliterans
• With gross hematuria, occult bleeding in urine of greater than or equal to 1+ and urine protein of greater than or equal to 1+, or either of greater than or equal to 2+ is found at screening
• Has a clinically significant vasculitis (e.g., mononeuritis multiplex)
• Known to be positive for human immunodeficiency virus antigen/antibody (HIV antigen/antibody), hepatitis B virus surface antigen (HBs antigen), hepatitis B virus surface antibody (HBs antibody), hepatitis B core virus antibody (HBc antibody), hepatitis B virus (HBV) DNA, hepatitis C virus antibody (HCV antibody), human T cell lymphotropic virus type 1 antibody (HTVL-1 antibody), or syphilis serology test positive at screening.
• Known to be positive for tuberculosis test (T-spot.TB Test or QuantiFERON TB Gold Test) at screening.
• Treated with ethical drug (except for disinfectants, eye drops) within 4 weeks before the study treatment.
• Treated with non-prescription drug (except for disinfectants, eye drops) within 2 weeks before the study treatment.
• Has participated in another clinical trial and received an investigational drug or device within 16 weeks before the study treatment.
• Received blood transfusion within 1 year, 400 mL or more whole blood donation within 12 weeks, or 200 mL or more whole blood donation within 4 weeks, or blood constituent donation within 2 weeks before the study treatment.

Sponsors & Collaborators

• Eisai Co., Ltd.: lead

Study Sites (1)

Unknown Facility

Sagamihara, Kanagawa, Japan

Location

MeSH Terms

Interventions

quetmolimab

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 21, 2014
• First Posted: May 23, 2014
• Study Start: September 1, 2013
• Primary Completion: December 1, 2013
• Study Completion: April 1, 2014
• Last Updated: October 22, 2014

Record last verified: 2014-05

Locations

JP (1)